[go: up one dir, main page]

UY34931A - ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. - Google Patents

?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.

Info

Publication number
UY34931A
UY34931A UY0001034931A UY34931A UY34931A UY 34931 A UY34931 A UY 34931A UY 0001034931 A UY0001034931 A UY 0001034931A UY 34931 A UY34931 A UY 34931A UY 34931 A UY34931 A UY 34931A
Authority
UY
Uruguay
Prior art keywords
rosuvastatin
oral administration
composite formulation
includes metformin
metformin
Prior art date
Application number
UY0001034931A
Other languages
English (en)
Inventor
Jin Cheul Kim
Jae Ho Kim
Jae Hyun Park
Jong Soo Woo
Ki Woo Jeong
Yong Ii Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY34931A publication Critical patent/UY34931A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan una formulación compuesta para administración oral que comprende metformina y rosuvastatina y un método para la preparación de las mismas. La formulación compuesta de acuerdo con la presente invención exhibe excelentes efectos sobre la prevención y tratamiento de la dislipidemia y hipercolesterolemia y muestra excelente estabilidad al almacenamiento, y de este modo puede usarse e fectivamente para el tratamiento de dislipidemia y hipercolesterolemia en un paciente diabético.
UY0001034931A 2012-07-24 2013-07-23 ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?. UY34931A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120080347A KR20140013436A (ko) 2012-07-24 2012-07-24 메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제

Publications (1)

Publication Number Publication Date
UY34931A true UY34931A (es) 2013-09-02

Family

ID=49223464

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034931A UY34931A (es) 2012-07-24 2013-07-23 ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.

Country Status (5)

Country Link
KR (1) KR20140013436A (es)
AR (1) AR092356A1 (es)
TW (1) TWI573587B (es)
UY (1) UY34931A (es)
WO (1) WO2014017833A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150201B1 (en) * 2014-06-30 2020-02-19 Hanmi Pharm. Co., Ltd. Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation
BR112016030731A2 (pt) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd Preparação de compósito, e, método de preparação de uma preparação de compósito
WO2016003180A1 (ko) * 2014-06-30 2016-01-07 한미약품 주식회사 5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
CN104523650B (zh) * 2014-12-20 2017-04-12 山东新时代药业有限公司 一种含有瑞舒伐他汀钙的胶囊
KR101526825B1 (ko) * 2014-12-23 2015-06-08 주식회사 한독 당뇨병 치료용 약제학적 조성물
WO2018093144A1 (ko) * 2016-11-15 2018-05-24 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 복합제제
KR102687535B1 (ko) * 2018-07-06 2024-07-24 한미약품 주식회사 무정형의 다파글리플로진 l-프롤린을 포함하는 약학적 제제 및 이의 제조방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
CN102458117B (zh) * 2009-05-01 2015-11-25 阿普塔利斯医药科技公司 含有非阿片样和阿片样止痛药的组合的口腔崩解片组合物
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
JP5662475B2 (ja) * 2009-12-30 2015-01-28 ビーシーワールド ファーム． カンパニー リミテッド メトホルミン及びロスバスチンを含む医薬組成物

Also Published As

Publication number Publication date
WO2014017833A1 (en) 2014-01-30
KR20140013436A (ko) 2014-02-05
AR092356A1 (es) 2015-04-15
TWI573587B (zh) 2017-03-11
TW201408283A (zh) 2014-03-01

Similar Documents

Publication Publication Date Title
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CR20150326A (es) Inhibidores de autotaxina
DK2925272T3 (da) Lægemiddelopbevarings-, udleverings- og administrationssystem
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
PH12019500176A1 (en) Heterocyclic compounds and ther uses
NI201600071A (es) Compuestos de inhibidor de autotaxina
CL2015000345A1 (es) Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib.
PL2925293T3 (pl) Formulacje tetracykliny do stosowania miejscowego, ich przygotowanie i zastosowania
UY34581A (es) Dispositivo de inhalación para fármacos en polvo
EP2953618A4 (en) MANIPULATION-SAFE PHARMACEUTICAL FORMULATIONS
CL2011000481S1 (es) Aplicador para cuidado oral.
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
UY34931A (es) ?formulación compuesta para administración oral que comprende metformina y rosuvastatina?.
MX2015012416A (es) Compuestos heterociclicos y sus usos.
FR3013218B1 (fr) Composition comprenant des capsules gelifiees stabilisees par un tampon
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
UY34579A (es) Dispositivo de inhalación para fármacos en polvo
UY34786A (es) Procedimiento para la fabricación de una forma farmacéutica que comprende nifedipino y candesartan cilexetilo
CL2014002951A1 (es) (r)-nifuratel; formulacion farmaceutica que lo contiene; y proceso para fabricar (r)-nifuratel y (s)-nifuratel.
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
UY36292A (es) Compuestos de tetrahidroquinolina para su uso como inhibidores de bromodominios
UY34829A (es) Nueva dosificación y formulación
EP2968195A4 (en) PHARMACEUTICAL FORMULATION WITH GLYCOSAMINOGLYCAN
EP2899198A4 (en) SYNTHETIC PNTX (19) -EPEPTIDES, PHARMACEUTICAL COMPOSITIONS AND USES

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210602